# US 2017/0290822 A1 · Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0290822 A1
- Document ID: US20170290822A1
- Status: Published application
- Kind: A1
- Application number: 15/633,132
- Filed: 2017-06-26
- Published: 2017-10-12
- Earliest claimed: 2012-02-03
- Assignees: Teva Pharmaceutical Industries Ltd.
- Inventors: Nora Tarcic; Asi Haviv; Eran Blaugrund; Joel Kaye
- Web page: https://patentgrep.com/patent/US20170290822A1

## CPC

- A61K 31/4704: 2-Quinolinones, e.g. carbostyril
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 215/56: with oxygen atoms in position 4
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This application provides for a method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.

## Claims

### Claim 1

A method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Crohn's disease is non-fibrostenotic Crohn's disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein the Crohn's disease is inflammatory Crohn's disease.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the Crohn's disease is steroid refractory Crohn's disease.

### Claim 5 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the patient has been administered oral steroids at baseline.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the patient's Crohn's disease had not been surgically treated.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the Crohn's disease is refractory to anti-TNFα treatment using infliximab, adalimimab, certolizumab or natalizumab.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the patient is naïve to anti-TNFα treatment.

### Claim 9

A method of treating a human patient afflicted with non-fibrostenotic Crohn's disease, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient.

### Claim 10 (depends on 9)

The method of claim 9, wherein the non-fibrostenotic Crohn's disease is inflammatory Crohn's disease.

### Claim 11 (depends on 9)

The method of claim 9, wherein the patient has been administered oral steroids at baseline.

### Claim 12 (depends on 10, 11)

The method of claim 10 or 11, wherein the Crohn's disease is steroid refractory Crohn's disease.

### Claim 13 (depends on 10, 11, 12)

The method of any one of claims 10-12, wherein the patient's Crohn's disease had not been surgically treated.

### Claim 14

A method of treating a human patient afflicted with Crohn's disease, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient, wherein the patient's Crohn's disease had not been surgically treated.

### Claim 15 (depends on 14)

The method of claim 14, wherein the Crohn's disease is steroid refractory Crohn's disease.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of claim any one of claims 1-15, wherein the amount of laquinimod is effective to reduce a symptom of Crohn's disease in the subject, induce clinical response, induce or maintain clinical remission, inhibit disease progression, or inhibit a disease complication in the subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the amount of laquinimod is effective to induce clinical remission in the patient.

### Claim 18 (depends on 16)

The method of claim 16, wherein the amount of laquinimod is effective to maintain clinical remission in the patient.

### Claim 19 (depends on 16)

The method of claim 16, wherein the amount of laquinimod is effective to induce and maintain clinical remission in the patient.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of claim any one of claims 1-19, wherein the pharmaceutically acceptable salt of laquinimod is laquinimod sodium.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of claim any one of claims 1-20, wherein the periodic administration is oral.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of claim any one of claims 1-21, wherein the amount is administered by a unit dose of 0.25 mg of laquinimod.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of claim any one of claims 1-21, wherein the amount is administered by a unit dose of 0.5 mg of laquinimod.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of claim any one of claims 1-23, wherein the periodic administration is daily administration.

### Claim 25 (depends on 24)

The method of claim 24, wherein the amount of laquinimod is 0.1-1.0 mg/day.

### Claim 26 (depends on 24)

The method of claim 24 wherein the amount of laquinimod is 0.1-0.75 mg/day.

### Claim 27 (depends on 24)

The method of claim 24, wherein the amount of laquinimod is 0.3-0.7 mg/day.

### Claim 28 (depends on 24)

The method of claim 24, wherein the amount of laquinimod is 0.25 mg/day.

### Claim 29 (depends on 24)

The method of claim 24, wherein the amount of laquinimod is 0.5 mg/day.

### Claim 30 (depends on 24)

The method of claim 24, wherein the amount of laquinimod is 1.0 mg/day.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the laquinimod is administered as adjunct therapy with an other Crohn's disease treatment.

### Claim 32

Use of laquinimod for treating a patient afflicted with anti-TNFα refractory Crohn's disease.

### Claim 33

A pharmaceutical composition comprising laquinimod for use in treating a patient afflicted with anti-TNFα refractory Crohn's disease.

### Claim 34

Use of laquinimod for treating a patient afflicted with non-fibrostenotic Crohn's disease.

### Claim 35

A pharmaceutical composition comprising laquinimod for use in treating a patient afflicted with non-fibrostenotic Crohn's disease.

### Claim 36

Use of laquinimod for treating a patient afflicted with Crohn's disease, wherein the Crohn's disease had not been surgically treated.

### Claim 37

A pharmaceutical composition comprising laquinimod for use in treating a patient afflicted Crohn's disease, wherein the Crohn's disease had not been surgically treated.

### Claim 38

A method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day.

### Claim 39 (depends on 38)

The method of claim 38, wherein the amount of laquinimod is effective to induce clinical remission in the patient.

### Claim 40 (depends on 38)

The method of claim 38, wherein the amount of laquinimod is effective to maintain clinical remission in the patient.

### Claim 41 (depends on 38)

The method of claim 38, wherein the amount of laquinimod is effective to induce and maintain clinical remission in the patient.

### Claim 42 (depends on 38, 39, 40, 41)

The method of any one of claim 38-41, wherein the amount of laquinimod 0.1-0.45 mg/day.

### Claim 43 (depends on 42)

The method of claim 42, wherein the amount of laquinimod is 0.25 mg/day.

### Claim 44

Use of a daily dose of less than 0.5 mg/day laquinimod for inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease.

### Claim 45

A pharmaceutical composition comprising a unit dose of less than 0.5 mg laquinimod for inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease.
